🚨 #ESMO26 小细胞肺癌（SCLC）重大研究结果公布！
III期 DeLLphi-305（N=563）：tarlatamab + durvalumab 对比 durvalumab 一线维持治疗，用于 ES-SCLC。
中位 OS：21.1 vs 12.7 个月
HR 0.42（95% CI 0.32–0.54）
12个月 OS：79.4% vs 53.3%
这是一项重要的生存获益。#LCSM
178 浏览 · 9 赞 · 4 转发 · 3 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- gilberto lopes@GlopesMd
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
- gilberto lopes@GlopesMd
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
- gilberto lopes@GlopesMd
PFS: 7.4 vs 1.9 mo (HR 0.34) ORR: 26.4% vs 4.1% Safety: • Grade ≥3 TEAEs: 46.8% vs 40.6% • CRS: 49.6% vs 1.4% (grade ≥3: 0.4% vs 0) • ICANS: 1.1% vs 0; none grade ≥3 Next: sequencing, biomarkers, CNS outcomes, QoL & access. Sands et al. LBA3.
来源：gilberto lopes · x.com